Baculoviral IAP repeat-containing protein 5 (Survivin) and Telomerase reverse transcriptase (hTERT) (Survivin and hTERT)

Survivin (Baculoviral IAP repeat-containing protein 5) and Human Telomerase Reverse Transcriptase (hTERT) are two critical tumor-associated antigens (TAAs) that are overexpressed in the majority of human malignancies while remaining largely absent in normal adult tissues (Source: PubMed, PMID: 12778136). Survivin is a member of the inhibitor of apoptosis (IAP) family that functions to inhibit caspase activity and regulate the cell cycle, specifically during the G2/M phase (Source: UniProt, O15392). hTERT is the catalytic subunit of the telomerase enzyme complex, which is responsible for maintaining telomere length and enabling the replicative immortality of cancer cells (Source: UniProt, O14746). Because these two proteins are essential for the survival and proliferation of malignant cells, they are frequently targeted in combination therapies, such as multi-peptide cancer vaccines like UV1, to prevent tumor escape (Source: ClinicalTrials.gov, NCT01794169). Pharmacological interventions include small molecule inhibitors like YM155 (Sepantronium bromide) that suppress Survivin expression and Imetelstat, which competitively inhibits telomerase activity (Source: PubChem, CID 11354563). Therapeutic targeting of these molecules aims to trigger apoptosis, induce cellular senescence, and stimulate a robust cytotoxic T-cell response against the tumor (Source: NIH, National Cancer Institute).

Other names

BIRC5TERTAPI4IAP4EST2TCS1TP2

Inhibition of BIRC5 expression, inhibition of telomerase enzymatic activity, and induction of cytotoxic T-lymphocyte responses against tumor-associated antigens.